Entry into a Material Definitive

New Office Lease

On February1, 2019, Millendo Therapeutics,Inc. (the Company) and Ann Arbor Real Estate Group, L.L.C. (the Landlord) entered into a Lease Agreement effective as of December 12, 2018 (the Lease), pursuant to which the Company will lease approximately 11,000 rentable square feet located at 110 Miller Avenue, Ann Arbor, Michigan (the Premises). The Premises, which the Company plans to occupy in the first half of 2019, will serve as the Companys new corporate headquarters. The Lease term commences on the date that is seven days after the date on which the Landlord delivers the Premises to the Company. The anticipated delivery date of the Premises is April1, 2019. The term of the Lease will be five years following the seventh day after the delivery dat e of the Premises. The Lease provides for two options to extend the Lease term for a period of five years each, each of which would commence upon the expiration of the then-current term, with base rent that will increase 3% over the prior twelve month periods base rent. The monthly base rent for the Premises for the first year will be $31,166.67 per month, which base rent will increase by 3% each subsequent year during the Lease term. The Landlord has agreed to provide the Company with an allowance of $121,000 for improvements to the first or third floor of 110 Miller Avenue.

Amendment and Restatement of Existing Lease

On February1, 2019, the Company entered into an amendment and restatement (the Amended and Restated Lease Extension) to the Lease Extension and Modification Agreement, originally dated as of October22, 2018, by and between the Company and 301 N. Main Street, LLC (the Current Landlord), pursuant to which the Company and the Current Landlord agreed to extend the term of the lease, dated as of December31, 2017, by and between the Company and the Landlord (the Current Lease), specify the rent due during the extension period and provide a renewal option to the Current Lease. The Amended and Restated Lease Extension and the Current Lease are for the premises located at 301 N. Main Street, Suite100, Ann Arbor, Michigan, which premises serve as the Companys current corporate headquarters. Under the terms of the Amended and Restated Lease Extension, the term of the Current Lease will be extended from December31, 2018 until March31, 2019 for a base rent of $11,720 per month. Following the expiration of the Current Lease on March31, 2019, the Company will have the option to extend the Current Lease on a month-to-month basis on the same terms and conditions set forth in the Current Lease and the Amended and Restated Lease Extension.

The foregoing summaries of the Lease and the Amended and Restated Lease Extension do not purport to be complete and are qualified in their entirety by reference to the full text of the Lease and the Amended and Restated Lease Extension, full copies of which are filed as exhibits to this Report.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 above is incorporated by reference here.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit

No.

Description

10.1

Lease Agreement.

10.2

Amended and Restated Lease Extension and Modification Agreement.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MILLENDO THERAPEUTICS,INC.

Date: February7, 2019

By:

/s/ Julia C. Owens, Ph.D.

Julia C. Owens, Ph.D.

President and Chief Executive Officer

3

makes a similar move, sign up!

Other recent filings from the company include the following:

OvaScience: Millendo Therapeutics Provides Corporate And Pipeline Update - June 23, 2020
OvaScience, Inc. director was just granted 12,000 options - June 23, 2020
OvaScience, Inc. director was just granted 12,000 options - June 23, 2020
OvaScience, Inc. director was just granted 12,000 options - June 23, 2020
OvaScience, Inc. director was just granted 12,000 options - June 23, 2020

Auto Refresh

Feedback